神戸大学附属図書館デジタルアーカイブ
入力補助
English
カテゴリ
学内刊行物
ランキング
アクセスランキング
ダウンロードランキング
https://hdl.handle.net/20.500.14094/0100487694
このアイテムのアクセス数:
35
件
(
2024-06-12
22:53 集計
)
閲覧可能ファイル
ファイル
フォーマット
サイズ
閲覧回数
説明
0100487694 (fulltext)
pdf
1.33 MB
18
メタデータ
ファイル出力
メタデータID
0100487694
アクセス権
open access
出版タイプ
Version of Record
タイトル
Reappraisal of a Renovated Cell-free and Concentrated Ascites Reinfusion Therapy for Malignant Ascites
著者
Kim, Yongsik ; Ajiki, Tetsuo ; Ueda, Yasuhiro ; Yoshida, Yuko ; Takahashi, Tsuyoshi ; Fukuyama, Hitoshi ; Fukuyama, Tsuyoshi ; Hori, Yuichi
著者名
Kim, Yongsik
著者ID
A0789
研究者ID
1000080379403
著者名
Ajiki, Tetsuo
味木, 徹夫
アジキ, テツオ
所属機関名
医学部附属病院
著者名
Ueda, Yasuhiro
著者名
Yoshida, Yuko
著者名
Takahashi, Tsuyoshi
著者名
Fukuyama, Hitoshi
著者名
Fukuyama, Tsuyoshi
著者ID
A0801
研究者ID
1000080248004
KUID
https://kuid-rm-web.ofc.kobe-u.ac.jp/search/detail?systemId=e28a2779b17cb7b0520e17560c007669
著者名
Hori, Yuichi
堀, 裕一
ホリ, ユウイチ
所属機関名
保健学研究科
収録物名
Anticancer Research
巻(号)
44(2)
ページ
613-619
出版者
International Institute of Anticancer Research
刊行日
2024-02
公開日
2024-03-27
抄録
Background/Aim: Cell-free and concentrated ascites reinfusion therapy (CART) was established for refractory ascites and renovated CART (Keisuke Matsusaki (KM) -CART) has been recently developed especially for malignant ascites; however, the actual clinical efficacy of KM-CART has been rarely reported. Patients and Methods: We performed 226 KM-CART procedures in 104 patients with malignant ascites in three hospitals from August 2013 to September 2018. Medical records were retrospectively reviewed for ascites data, related complications, symptoms before and after each CART and prognosis after the first CART. The modified Glasgow Prognostic Score (mGPS) was reviewed before every procedure, as an indicator of nutritional status. Results: Pancreatic cancer was the most common indication for the KM-CART procedure, followed by gastric cancer, hepatocellular carcinoma, ovarian cancer, and cholangiocarcinoma (five major diseases). The 50% survival times of these five major diseases after the first procedure were 25, 39, 31, 49, and 33 days, respectively. The mean survival time for all patients was 73.5 days, and 75.6 days for those with the five major diseases. All patients experienced symptomatic relief, and complications were rare. Repeated KM-CART was performed in 47.1% of the patients, most often in those with ovarian cancer (66.7%). Regarding the mGPS at the first CART procedure, 89% of patients were in the group with the poorest nutritional status. Patients who underwent KM-CART three or more times had longer survival than those who were treated once or twice. Conclusion: Repeated KM-CART provides a survival benefit for patients with malignant ascites, even in cases of poor nutritional status.
キーワード
Renovated cell-free and concentrated ascites reinfusion therapy
KM-CART
Modified Glasgow Prognostic Score (mGPS)
prognosis
cumulative survival rate
カテゴリ
医学部附属病院
保健学研究科
学術雑誌論文
権利
© 2024 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International license.
詳細を表示
資源タイプ
journal article
言語
English (英語)
ISSN
0250-7005
OPACで所蔵を検索
CiNiiで学外所蔵を検索
eISSN
1791-7530
OPACで所蔵を検索
CiNiiで学外所蔵を検索
関連情報
DOI
https://doi.org/10.21873/anticanres.16850
ホームへ戻る